BARDA entered into a partnership with Siemens Healthineers to accelerate development of the SARS-CoV-2 total antibody test. This laboratory-based total antibody test can be used to detect the presence of both SARS-CoV-2 IgM and the longer-lasting IgG antibodies in human serum and plasma. Serology-based tests like the SARS-CoV-2 total antibody test can be used as an aid in identifying patients with an adaptive immune response to SARS-CoV-2, indicating a recent or prior infection.
Siemens has over 2,000 fully automated immunoassay analyzers in hospitals and mid to high volume reference laboratories across all 50 states. Siemens immunoassay analyzers include the Atellica® IM which can run up to 440 tests per hour with a result in 10 minutes and the ADVIA Centaur® XP and XPT analyzers, which can test up to 240 samples per hour with a result in 18 minutes.
Starting in June, Siemens Healthineers will ramp up production at the company’s facilities in Walpole, Massachusetts, and Newark, Delaware, with capacity exceeding 50 million antibody tests per month.
Both the Atellica® IM SARS-CoV-2 Total (COV2T) and the ADVIA Centaur® SARS-CoV-2 Total (COV2T) were granted Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) on May 29, 2020.
This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.
About the Company:
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. Further information is available at www.siemens-healthineers.com.
Be the first to know about BARDA news and new awards. Sign-up for our email announcements:
